BD 211
Alternative Names: BD-211Latest Information Update: 25 Jun 2024
At a glance
- Originator Shanghai BDgene
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Beta-thalassaemia
- Preclinical Sickle cell anaemia
Most Recent Events
- 25 Jun 2024 Preclinical trials in Sickle cell anaemia in China (IV)(Shanghai BDgene pipeline, June 2024)
- 28 May 2024 No recent reports of development identified for phase-I development in Beta-thalassaemia(In adolescents, In children, In adults) in China (Parenteral, Infusion)
- 05 Jan 2024 BD 211 is still in phase-I development in Beta-thalassaemia(In adolescents, In children, In adults) in China (Parenteral, Infusion) (NCT05015920)